• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Cel-Sci Corp (NY: CVM )

    1.620 -0.010 (-0.61%)
    Streaming Delayed Price Updated: 11:10 AM EDT, May 6, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 215,861
    Open 1.670
    Bid (Size) 1.620 (3)
    Ask (Size) 1.630 (3)
    Prev. Close 1.630
    Today's Range 1.600 - 1.750
    52wk Range 1.040 - 3.230
    Shares Outstanding 50,104,231
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    CEL-SCI Appoints Mario Gobbo to Its Board of Directors
    From CEL-SCI Corporation
    Via Business Wire
    CEL-SCI’s LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology
    From CEL-SCI Corporation
    Via Business Wire

    Performance

    YTD
    -39.78%
    -39.78%
    1 Month
    -8.47%
    -8.47%
    3 Month
    -44.52%
    -44.52%
    6 Month
    -30.47%
    -30.47%
    1 Year
    -35.20%
    -35.20%

    More News

    Read More
    CEL-SCI Corporation Issues Letter to Shareholders
    From CEL-SCI Corporation
    Via Business Wire
    Why CEL-SCI Corporation (CVM) Shares Are Diving
    Via Benzinga
    CVM Stock Earnings: CEL-SCI Reported Results for Q4 2023
    Via InvestorPlace
    CEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial Results
    From CEL-SCI Corporation
    Via Business Wire
    InvestorNewsBreaks – CEL-SCI Corporation (NYSE American: CVM) Closes on $7.75M Public Offering
    Via Investor Brand Network
    Exposures Product Safety
    CEL-SCI Announces Closing of $7.75 Million Public Offering of Common Stock
    From CEL-SCI Corporation
    Via Business Wire
    12 Health Care Stocks Moving In Friday's Intraday Session
    Via Benzinga
    CEL-SCI Announces Pricing of $7.75 Million Public Offering of Common Stock
    From CEL-SCI Corporation
    Via Business Wire
    CEL-SCI Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head & Neck Cancer Drug
    From CEL-SCI Corporation
    Via Business Wire
    European Medicines Agency Grants CEL-SCI a Waiver of Strict Pediatric Requirements, Clearing the Path Towards Marketing Authorization for Multikine®
    From CEL-SCI Corporation
    Via Business Wire
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Via Benzinga
    CEL-SCI Reports Fiscal 2023 Financial Results and Clinical & Corporate Developments
    From CEL-SCI Corporation
    Via Business Wire
    Why U Power Shares Are Trading Lower By Around 54%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Intraday Session
    Via Benzinga
    Why Is Cancer Focused CEL-SCI Stock Trading Higher Today?
    Via Benzinga
    UK’S National Institute for Health and Care Excellence (NICE) Selects CEL-SCI’s Multikine as Potential New Standard of Care for Head & Neck Cancer
    From CEL-SCI Corporation
    Via Business Wire
    CEL-SCI Announces Closing of $5 Million Public Offering of Common Stock
    From CEL-SCI Corporation
    Via Business Wire
    CEL-SCI Announces Pricing of $5 Million Offering of Common Stock
    From CEL-SCI Corporation
    Via Business Wire
    CEL-SCI Issues Letter to Shareholders
    From CEL-SCI Corporation
    Via Business Wire
    Why the Relapsed/Refractory Acute Myeloid Leukemia Market is Expected to Witness Revolutionary Developments
    Via FinancialNewsMedia
    Exposures Product Safety
    CEL-SCI Releases Video Detailing Recent Phase 3 Findings & its Plans to Seek Immediate Regulatory Approvals
    From CEL-SCI Corporation
    Via Business Wire
    5-Year Head & Neck Cancer Survival Increased From 45% to 73% in CEL-SCI’s Target Population, Cutting Risk of Death in Half, as Presented at Leading Cancer Conference ESMO 2023
    From CEL-SCI Corporation
    Via Business Wire
    CEL-SCI Readies Its Multikine Manufacturing Facility for Commercial Scale Production
    From CEL-SCI Corporation
    Via Business Wire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.